COMP <GO>
ZBH vs MRK // FORWARD P/E MULTIPLE
Zimmer Biomet Holdings Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ZBH 5
— MRK 9
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $97.35 (+2.99%) • MKT CAP: $18.57B
forward-pe
24.6x
LAST: $148.36 (-0.78%) • MKT CAP: $366.03B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZBH VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZBH | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.70% | 74.80% | -5.10 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 20.70% | -16.10 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.3x | 15.3x | +4.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 7.92% | 3.42% | +4.50 | ZBH | /fcf-yield <GO> |
| Operating Margin | 13.30% | 34.30% | -21.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 8.60% | 28.10% | -19.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 7.20% | 1.30% | +5.90 | ZBH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.02% | 2.26% | -1.24 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.42 | 5.19 | -2.77 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ZBH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.5 | 54.3 | +1.20 | ZBH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.92 | +0.10 | ZBH | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 24.6x | 18.4x | +6.20 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.57B | $366.03B | -$347.46B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZBH REV | MRK REV | ZBH GROSS % | MRK GROSS % | ZBH FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.23B | $65.01B | 69.7% | 74.8% | $1.47B | $12.36B |
| FY 2024 | $7.68B | $64.17B | 71.5% | 76.3% | $1.30B | $18.10B |
| FY 2023 | $7.39B | $60.12B | — | — | $1.25B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZBH // BETA 1.02
MRK // BETA 0.92